Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer.
Fabrice Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Richard Greil
No relevant relationships to disclose
Neelima Denduluri
No relevant relationships to disclose
Alejandro Javier Yovine
Employment or Leadership Position - Novartis
Cathy Reddick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (B)
Matthew Squires
Employment or Leadership Position - Novartis
Yong Zhang
Employment or Leadership Position - Novartis
Kimberly Blackwell
No relevant relationships to disclose